Travers et al.[13] illustrated that medicine with the combination of 5-azacytidine (5AZA-C) and α-difluoromethylornithine (DFMO) can induce the recruiting process of activated CD8+ T-cells, IFNγ+ CD4+ T-cells (Th1), and NK cells, while significantly reducing immunosuppressive cells like M2-polarized macrophages and increasing tumor-killing M1 macrophages, in the TIME of patients with OC. The gene discussed is IFNG; the disease is neoplasm.